MOST SHARED
- Ritz-Carlton ?Struggling? in the US: President
- Garlic Price Rises Surpass Gold, Stocks in China
- New-Home Sales Jump 6.2% To Highest Level in Over Year
- S&P Stocks Trading at New 52-Week Highs
- Half of Banks' Losses May Still Be Hidden: IMF Head
- Oil Price to Average $75.40 in 2010: Poll
- Americans Ditch Planes for Trains this Thanksgiving
- Jobless Claims Below 500,000, Durable Orders Slip
- Consumer Mood Improves, But Anxiety Over Personal Finances
- A Facebook Christmas
- For Many in US, It Will Be a Scaled-Down Holiday Season
- Judge Erases Couple's $525,000 Mortgage Payment
- Where Do Pardoned Turkeys Go?
- Foreign Demand Boosts US 7-Year Treasury Sale
- New-Home Sales Jump to Highest Level in Over Year
- Consumers Catching the Holiday Spirit
- Jobless Claims Below 500,000, Durable Orders Slip
- Activision Prepares to Double Dip on ‘Modern Warfare 2’
- Garlic Price Rises Surpass Gold, Stocks in China
- Retail Earnings and Sales to Improve in Q4: Analyst
- Consumers Catching the Holiday Spirit
- It's Beginning To Look A Lot More Riskless
- Crescenzi: Claims Level Suggests End to Job Losses
- Hedge Funds Take Early Lead in Warren Buffett's 'Big Bet'
- S&P Stocks Trading at New 52-Week Highs
- 4 Food Stocks to Stuff in Your Portfolio: Analyst
- S&P at 1050-1200 Trading Range Next Year: Strategist
- Treasury On Mortgage Modifications
NEW YORK, Nov 05, 2009 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue.
The Global Antibacterials Market: R&D Pipelines, Market Analysis and Competitive Landscape http://www.reportlinker.com/p0158348/The-Global-Antibacterials-Market-RD-Pipelines-Market-Analysis-and-Competitive-Landscape.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire The global anti-infective market is currently valued at US$66.5 billion with antibacterial agents accounting for over 50% of sales. The antibacterial market is set to grow to over US$45.0 billion by 2012, driven by the uptake of newer antibacterial agents such as glycopeptides and carbapenems which demonstrate resistance to methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE) as well as other emerging strains.
Pharmaceutical companies continue to develop a new generation of antibacterial agents such as cephalosporins, macrolides and quinolones to overcome the major issue of drug resistance. In addition, a number of new drug classes such as dihydrofolate reductase inhibitors (DHFR) are under evaluation which are effective in multi drug resistant organisms.
This report examines each of the antibacterial classes in turn, assessing the market potential and application in hospital and community-acquired infections.
The following product classes are analyzed in this report: -- aminoglycosides -- carbapenems -- cephalosporins -- dihydrofolate reductase inhibitors -- glycopeptides -- ketolides -- lipopeptides -- macrolides -- penicillins -- oxazolidinones -- pleuromutulins -- quinolones The report assesses the overall antibacterial market, key classes and the drivers and resistors influencing their prescription. The report provides an overview of key products in each category, summarizing their clinical efficacy and marketing position. The overview of the current market is given in terms of segmentation and by leading players and their products and analyzes market trends.
The report also examines promising pipeline products and their potential impact on the prescription of current and new antibacterial agents and the future of the antibacterial market.
Key Features of this report: -- Overview of the antibacterial market, including the main infectious agents, therapeutic drug classes and key players.
-- In-depth analysis of different classes of antibacterial agents, including leading antibacterial agents and a summary of leading brands within each class.
-- Comprehensive facts and figures for the antibacterial market, including main players and drug class break-downs.
-- Future trends in the antibacterial marketplace, driven by drug resistance and patient demographics.
-- Outlook for the antibacterial market, including the emergence of novel therapies and the impact of generics.
1 EXECUTIVE SUMMARY To order this report: The Global Antibacterials Market: R&D Pipelines, Market Analysis and Competitive Landscape http://www.reportlinker.com/p0158348/The-Global-Antibacterials-Market-RD-Pipelines-Market-Analysis-and-Competitive-Landscape.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire More market research reports here!
Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626 SOURCE Reportlinker URL: http://www.reportlinker.com www.prnewswire.com Copyright (C) 2009 PR Newswire. All rights reserved -0- KEYWORD: New York INDUSTRY KEYWORD: HEA
IDC SUBJECT CODE: SVY



